Novel immunotherapeutic agents are transforming how we treat cancer and reshape the immune system’s role in care. With shorter monitoring windows, evolving toxicity profiles, and proven feasibility outside the hospital, the next generation of therapies demands new approaches to safety, staffing, and patient monitoring.
In this discussion, Current Health CMO Dr. Matt Wilkes joins Dr. Sridevi Rajeeve and Dr. Neha Korde, hematologist/oncologists at Memorial Sloan Kettering, to explore how they are advancing outpatient delivery of complex therapies and preparing for the future of care.